Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2016

View Archived Issues

Otsuka tuberculosis candidate granted U.S. orphan drug designation

DynPort Vaccine Company plague vaccine granted FDA orphan drug status

Neutralizing human MAbs protect against infection and maternal-fetal transmission of ZIKV in vivo

Ortho-McNeil-Janssen Pharmaceuticals and KU Leuven patent dengue viral replication inhibitors

Roche and Genentech disclose ERalpha ligands

Cardiome Pharma launches Xydalba in U.K.

FDA accepts durvalumab BLA for urothelial cancer

GlaxoSmithKline describes KMO inhibitors

3D microtissue engineering used to generate hypertrophic cardiomyopathy cardiomyocytes

Soligenix reports long-term follow-up data from phase II trial of SGX-942 for oral mucositis

New U.K. alliance established to accelerate development of treatments for arthritis

SNPs in BDNF and GSK-3beta may be associated with bipolar disorder

AstraZeneca initiates phase I study of abediterol and AZD-7594

E2F4 activation shows promise for SCI recovery

Phase III trials show no benefit in adding Fovista to Lucentis for wet AMD

New MGL inhibitor shows promise for the treatment of pain

Valeant Pharmaceuticals reports positive results from phase III study of IDP-118

Synergy reports results from first phase III trial of plecanatide for IBS-C

BioInvent terminates phase II study of BI-505 in multiple myeloma

New phase I trial explores use of PGT-121 for HIV prevention and therapy

Seattle Genetics initiates phase I trial of SGN-CD352A in relapsed or refractory multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...